With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.
The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug ...
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinctâ„¢ accelerators and ROCmâ„¢ software to power ...
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...
Evotec will bring to bear its world-class antibody development, engineering and manufacturing technologies together with its integrated preclinical R&D platforms for drug discovery and development ...
Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will ...
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...
Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...